BAYTRIL FLAVOUR 25 MG/ML ORAL SUSPENSION FOR CAT. ENROFLOXACIN.

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

ENROFLOXACIN

제공처:

Bayer Limited

ATC 코드:

QJ01MA90

INN (International Name):

ENROFLOXACIN

복용량:

25 Mg/Ml

약제 형태:

Oral Suspension

처방전 유형:

POM

치료 그룹:

Feline

치료 영역:

Enrofloxacin

치료 징후:

Antibacterial

승인 상태:

Authorised

승인 날짜:

2011-08-26

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Baytril flavour 25 mg/ml oral suspension for cat
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of the product contains:
ACTIVE SUBSTANCE:
Enrofloxacin
25 mg
EXCIPIENTS:
Ascorbic acid (E300)
0.2 mg
Sorbic acid (E200)
2 mg
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Oral suspension
White to yellow-white suspension
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cat
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of single or mixed bacterial infections of the respiratory, alimentary and urinary tract, skin or wounds
caused by the following enrofloxacin-sensitive Gram-negative and Gram-positive bacteria:
Staphylococci, _E. coli, Haemophilus _spp. and _Pasteurella _spp_._
4.3 CONTRAINDICATIONS
Do not use in
Animals with existing impairment of cartilage growth.
Animals with a known history of seizures_, _since enrofloxacin may cause CNS stimulation.
Animals with known hypersensitivity to fluoroquinolones or any of the excipients.
For use in pregnant animals see section 4.7 and for interactions with other medicinal products see section 4.8
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 27/05/2016_
_CRN 7022033_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not use in cases of known resistance to quinolones because of near-total cross-resistance with these compounds and
complete cross-resistance with other fluoroquinolones.
In animals where product administration is associated with excessive salivation or where difficulty administering the
required dose is experienced, administration should be discontinued and an alternative therapy used.
4.5 SPECIAL PRECAUTIONS